卢非酰胺治疗癫痫的效果好不好

This observational study collected retrospective data from multiple centers in Germany and Austria. The clinical course of patients receiving rufinamide was recorded. The initial dose and titration schedule of rufinamide is at the discretion of the treating physician based on medical necessity. The observation period is 12 weeks. Efficacy was assessed by comparing seizure frequency and countability limits between baseline and the final 4-week observation period.

Results: The study population included 45 children and 15 adults (mean age: 14.5+/-11.6 years, range: 1-50) with various severe and poorly controlled epilepsy syndromes, namely LGS (n=31), idiopathic generalized epilepsy syndrome (n=5), cryptogenic unclassified generalized epilepsy (n=7) and partial epilepsy (n=17).

The overall effective rate (50% reduction in countable seizures) was 46.7% (28 out of 60 patients); 25.0% of patients had a 75% reduction in seizures, and 21.7% had a 50-75% reduction in seizures. The complete epilepsy control rate was 8.3%. Patients with LGS had the highest response rate (17/31, 54.8%), and patients with partial epilepsy had the lowest response rate (4/17, 23.5%). The effective rate for patients with unclassified generalized epilepsy was 42.8% (3/7).

35 of 60 patients reported 67 cases. The most common adverse events were fatigue (18.3%), vomiting (13.3%), and loss of appetite (10.0%). No serious adverse events were observed.

Conclusions: These preliminary data suggest that rufinamide may be effective and well tolerated in children and adults with various epilepsy syndromes and difficulty in controlling seizures. The results of the study suggest that rufinamide may be as effective as LGS patients in patients with generalized epilepsy, but less effective in patients with partial epilepsy.

Rufinamide was originally successfully developed by Eisai, an American pharmaceutical company. It was approved by the U.S. FDA for marketing on November 14, 2008. It works by regulating the brain's voltage gate sodium ion channels. It has therapeutic benefits for partial epileptic seizures and generalized tonic-clonic seizures (tonic-clonic seizures), and can be administered in combination or alone. Rufinamide is effective as an adjunctive therapy in reducing the frequency of symptomatic seizures in patients with drug-resistant focal epilepsy. It is recommended that patients take medication as directed by their doctor and receive symptomatic treatment.

Recommended related articles:

References

Kluger G, Kurlemann G, Haberlandt E, Ernst JP, Runge U, Schneider F, Makowski C, Boor R, Bast T. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav. 2009 Mar;14(3):491-5. doi: 10.1016/j.yebeh.2008.12.013. Epub 2009 Jan 20. PMID: 19162229.